## Manual 014

## 5.9 Audit Reporting Figure: 1

CAT	No	OBSERVATION	PROPOSED	BY WHOM	WHEN	PROGRESS	DATE	CLOSED
			FOLLOW-UP			COMMENTS	OBSERVATION	OUT BY
$\vdash$			ACTION				CLOSED OUT	

The report should clearly identify agreed deviations/deficiencies and indicate their classification, i.e. "CAT" in the first column above (critical, major, other) in accordance with the following table:

2004					
Class	Pharmaceutical active ingredients and pharmaceutical contractors	Pharmaceutical excipients, printed and primary packaging components	Chemical materials and miscellaneous packaging components	Action required from supplier	
Critical	Serious non compliance with cGMP/regulatory requirements that results in a significant risk to the patient/business	Serious failure of a procedure that results in a significant risk to the patient/business	Serious failure of a procedure that results in a significant risk to the customer's process or product/business	Immediate corrective action is mandatory. A time schedule for CAPA implementation is required	
Major	Significant non compliance with cGMP/regulatory requirements NOT directly offering a risk to the patient/business	Significant failure of a procedure NOT directly offering a risk to the patient/business	Significant failure of a procedure NOT directly offering a risk to the customer's process or product/business	A time schedule for CAPA implementation is required	
Minor (Other)	Failure to follow cGMP practise or specific AstraZeneca's requirement	Failure to follow an appropriate procedure	Failure to follow an appropriate procedure	A time schedule for CAPA implementation is recommended	

CAPA = Corrective And Preventive Action

Note: several majors can be collectively added to make a critical.

## 5.12 Audit Standards Figure 2

	Audit Standards								
Supplier of	ICH Q7A	IPEC - GMP Guide for Bulk Pharmaceutical Excipients	EU – GMP and/or PIC/S GMP	21 CFR - parts 210 & 211	21 CFR - part 820	ISO 9001:2000	PS 9000/PS9100	Other standards and guidances e.g. Aseptic processing	
Finished Drug Products (sterile and non-sterile)			х	х				х	
General Services*			Х	Х				Х	
Sterile API	Х		Х	Х				Х	
API	Х		Х	Х				Х	
Intermediate	Х			Х				х	
API starting materials (CRM)						X (with appropriate Q7a level of GMP)		х	
NCRM						Х		х	
Excipient		Х				Х	X**	х	
Sterile EX		X	Х	Х				Х	
PCC					Х	Х	X***	Х	
PCNC						Х		Х	
Microbiological supplier			Х	Х		Х		Х	